Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deborah Friedman

Neurology Dallas, TX Medical Doctor

NPI 1023036340 CMS profile 273310

12740 Hillcrest Rd Ste 269, Dallas, TX 75230

Open in the dashboard

General payments

$283,614

332 records reported · program years 2019–2025

Research payments

$6,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$342,905 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Deborah Friedman of Dallas, TX is reported in the CMS Open Payments database as having received $283,614 across 332 general payments and $6,000 in research payments paid to them. Separately, studies naming them as principal investigator received $342,905 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32,019 43
2024 General $66,948 49
2023 General $75,532 91
2022 General $34,715 40
2021 General $21,196 25
2020 General $15,855 13
2019 General $37,348 71
2019 Research $6,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deborah Friedman
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Deborah Friedman were reported at $32,019. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Deborah Friedman Neurology median Middle half National median
2019 $37,348 $474 $118–$2,177 $163
2020 $15,855 $367 $82–$2,309 $114
2021 $21,196 $438 $104–$2,547 $132
2022 $34,715 $442 $103–$2,388 $149
2023 $75,532 $464 $119–$2,312 $160
2024 $66,948 $468 $119–$2,323 $164
2025 $32,019 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $49,443 64 payments
  2. Pfizer Inc. $37,384 34 payments
  3. Axsome Therapeutics, Inc. $30,579 16 payments
  4. Lilly USA, LLC $28,510 56 payments
  5. Teva Pharmaceuticals USA, Inc. $26,385 39 payments
  6. Eli Lilly and Company $23,112 8 payments
  7. Lundbeck LLC $17,672 28 payments
  8. Pfizer International LLC $13,245 3 payments
  9. Biodelivery Sciences International, Inc. $8,957 12 payments
  10. Pfizer Chile S.A. $8,740 1 payment
  11. Other $39,588 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $106,939 35 payments
  2. Consulting Fee $93,894 33 payments
  3. Honoraria $37,013 12 payments
  4. Travel and Lodging $33,860 77 payments
  5. Food and Beverage $11,908 175 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $48,952 30 payments
  2. UBRELVY $44,073 50 payments
  3. QULIPTA $34,576 45 payments
  4. Symbravo $16,474 8 payments
  5. AJOVY Central Nervous System $14,026 25 payments
  6. Ajovy Central Nervous System $12,244 13 payments
  7. ELYXYB - CELECOXIB $8,957 12 payments
  8. ZAVZPRET $8,845 9 payments
  9. TROKENDI XR $8,144 14 payments
  10. Trudhesa $7,832 6 payments
  11. Other $18,567 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $6,000 1 payment

Records

333 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record